|
Post by ryster505 on Oct 4, 2018 13:01:51 GMT -5
Aged...Why are you even on this board? Other than your “expertise” On the disease of diabetes, you seem to always just be a downer.
|
|
|
Post by peppy on Oct 4, 2018 14:00:15 GMT -5
adisinsight.springer.com/drugs/800041818#disabledthe stimulants. Abstract URLi (LY900014), a novel ultra-rapid mealtime insulin in Phase 3 development, is shown to reduce postprandial glucose after subcutaneous injection. This 2-part, randomized, double-blind, Phase 1b study evaluated the differences in PK and PD between URLi and insulin lispro (Humalog®; HL) in 30 patients with T1D. Part A used a 6´period crossover design to evaluate safety and compare PK and postprandial glucose response to solid mixed meal tolerance tests (MMTT) with URLi or HL at different injection to mealtime intervals (-15, 0, and +15 min). Part B evaluated the safety, PK, and PD during 2 weeks of multiple daily dosing (immediately before a meal) in a parallel design. In Part A, URLi reduced glucose excursions (assessed as change in area under the concentration curve vs. time [∆AUC]) during the first 2 hours (∆AUC0-2h) and entire 5 hours (∆AUC0´5h) of the MMMT regardless of dose timing (Fig). URLi reduced ∆AUC0-2h by 103% (p=0.008), 39% (p=0.031), and 16% (p=0.096), and ∆AUC0-5h by 40% (p=NS), 44% (p=0.097), and 42% (p=0.026) vs. HL at -15, 0, and +15 min (significance level =0.1. The PK and PD profiles for URLi and HL were sustained after 2 weeks of outpatient dosing (Part B). Similar number of hypoglycemic events occurred between treatments during MMTTs. During 2 weeks of outpatient dosing, the number of events was lower for URLi vs. HL. Local tolerability was similar between treatments. diabetes.diabetesjournals.org/content/67/Supplement_1/1010-P
|
|
|
Post by agedhippie on Oct 4, 2018 14:04:39 GMT -5
RAAs aren't even insulin. No wonder people are confused You are flogging a dead horse there. Nobody cares.
|
|
|
Post by agedhippie on Oct 4, 2018 14:05:57 GMT -5
The new RAA insulins are far more about protecting market share than providing better insulin.
|
|
|
Post by agedhippie on Oct 4, 2018 14:09:39 GMT -5
Aged...Why are you even on this board? Other than your “expertise” On the disease of diabetes, you seem to always just be a downer. Diabetes is a downer. I have never met anyone who was happy at developing diabetes! Why I on the board? Same reason as a lot of others, for news on Afrezza.
|
|